Literature DB >> 34240697

SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data.

Dung Nguyen1, Peter Simmonds1, Maurice Steenhuis2, Elise Wouters3, Daniel Desmecht4, Mutien Garigliany4, Marta Romano5, Cyril Barbezange6, Piet Maes7, Bram Van Holm7, Joaquín Mendoza8, Salvador Oyonarte9, Anders Fomsgaard10, Ria Lassaunière10, Eva Zusinaite11, Katarina Resman Rus12, Tatjana Avšič-Županc12, Johan Hj Reimerink13, Fiona Brouwer13, Marieke Hoogerwerf13, Chantal Bem Reusken13, Gunnveig Grodeland14, Sophie Le Cam15, Pierre Gallian15,16, Abdennour Amroun16, Nadège Brisbarre16,17, Christophe Martinaud18, Isabelle Leparc Goffart19, Hubert Schrezenmeier20,21, Hendrik B Feys3, C Ellen van der Schoot2, Heli Harvala22,23.   

Abstract

We compared the performance of SARS-CoV-2 neutralising antibody testing between 12 European laboratories involved in convalescent plasma trials. Raw titres differed almost 100-fold differences between laboratories when blind-testing 15 plasma samples. Calibration of titres in relation to the reference reagent and standard curve obtained by testing a dilution series reduced the inter-laboratory variability ca 10-fold. The harmonisation of neutralising antibody quantification is a vital step towards determining the protective and therapeutic levels of neutralising antibodies.

Entities:  

Keywords:  Europe; SARS-CoV-2; convalescent plasma; neutralising antibodies; standardisation, COVID-19

Mesh：

Substances：

Year:  2021        PMID： 34240697     DOI： 10.2807/1560-7917.ES.2021.26.27.2100568

Source DB:  PubMed          Journal:  Euro Surveill        ISSN： 1025-496X


  12 in total

1.  A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern.

Authors:  Nina Urke Ertesvåg; Julie Xiao; Alain Townsend; Nina Langeland; Rebecca Jane Cox; Fan Zhou; Sonja Ljostveit; Helene Sandnes; Sarah Lartey; Marianne Sævik; Lena Hansen; Anders Madsen; Kristin G I Mohn; Elisabeth Fjelltveit; Jan Stefan Olofsson; Tiong Kit Tan; Pramila Rijal; Lisa Schimanski; Siri Øyen; Karl Albert Brokstad; Susanna Dunachie; Anni Jämsén; William S James; Adam C Harding; Heli Harvala; Dung Nguyen; David Roberts; Maria Zambon
Journal:  Commun Med (Lond)       Date:  2022-04-05

2.  Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma.

Authors:  Dung Nguyen; Julie Xiao; Peter Simmonds; Abigail Lamikanra; Valerie Odon; Jeremy Ratcliff; Alain Townsend; David J Roberts; Heli Harvala
Journal:  J Infect Dis       Date:  2022-03-15       Impact factor: 5.226

3.  Neutralisation of the SARS-CoV-2 Delta variant sub-lineages AY.4.2 and B.1.617.2 with the mutation E484K by Comirnaty (BNT162b2 mRNA) vaccine-elicited sera, Denmark, 1 to 26 November 2021.

Authors:  Ria Lassaunière; Charlotta Polacek; Jannik Fonager; Marc Bennedbæk; Lasse Boding; Morten Rasmussen; Anders Fomsgaard
Journal:  Euro Surveill       Date:  2021-12

Review 4.  Evidence-based dosing of convalescent plasma for COVID-19 in future trials.

Authors:  Bart J A Rijnders; Sammy Huygens; Oriol Mitjà
Journal:  Clin Microbiol Infect       Date:  2022-02-10       Impact factor: 13.310

5.  Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2.

Authors:  Ria Lassaunière; Charlotta Polacek; Gregers J Gram; Anders Frische; Jeanette Linnea Tingstedt; Maren Krüger; Brigitte G Dorner; Anthony Cook; Renita Brown; Tatyana Orekov; Tammy Putmon-Taylor; Tracey-Ann Campbell; Jack Greenhouse; Laurent Pessaint; Hanne Andersen; Mark G Lewis; Anders Fomsgaard
Journal:  NPJ Vaccines       Date:  2021-12-20       Impact factor: 7.344

6.  Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients.

Authors:  Pere Millat-Martinez; Arvind Gharbharan; Andrea Alemany; Casper Rokx; Corine Geurtsvankessel; Grigorios Papageourgiou; Nan van Geloven; Carlijn Jordans; Geert Groeneveld; Francis Swaneveld; Ellen van der Schoot; Marc Corbacho-Monné; Dan Ouchi; Francini Piccolo Ferreira; Pierre Malchair; Sebastian Videla; Vanesa García García; Anna Ruiz-Comellas; Anna Ramírez-Morros; Joana Rodriguez Codina; Rosa Amado Simon; Joan-Ramon Grifols; Julian Blanco; Ignacio Blanco; Jordi Ara; Quique Bassat; Bonaventura Clotet; Bàrbara Baro; Andrea Troxel; Jaap Jan Zwaginga; Oriol Mitjà; Bart J A Rijnders
Journal:  Nat Commun       Date:  2022-05-11       Impact factor: 17.694

7.  Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022.

Authors:  Rebecca Amati; Anja Frei; Marco Kaufmann; Serena Sabatini; Céline Pellaton; Jan Fehr; Emiliano Albanese; Milo A Puhan
Journal:  Euro Surveill       Date:  2022-08

8.  Optimization and evaluation of a live virus SARS-CoV-2 neutralization assay.

Authors:  Anders Frische; Patrick Terrence Brooks; Mikkel Gybel-Brask; Susanne Gjørup Sækmose; Bitten Aagaard Jensen; Susan Mikkelsen; Mie Topholm Bruun; Lasse Boding; Charlotta Polacek Strandh; Charlotte Sværke Jørgensen; Karen Angeliki Krogfelt; Anders Fomsgaard; Ria Lassauniere
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

9.  Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.

Authors:  Heli Harvala; Dung Nguyen; Peter Simmonds; Abigail A Lamikanra; Hoi Pat Tsang; Ashley Otter; Piet Maes; Mhairi Webster; Adam Clarkson; Fotini Kaloyirou; Valerie Hopkins; Stephen M Laidlaw; Miles Carroll; Ana Mora; Alexandra Griffiths; Sheila MacLennan; Lise Estcourt; David J Roberts
Journal:  Transfusion       Date:  2022-06-02       Impact factor: 3.337

Review 10.  COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes.

Authors:  Daniele Focosi; Massimo Franchini; Liise-Anne Pirofski; Thierry Burnouf; Nigel Paneth; Michael J Joyner; Arturo Casadevall
Journal:  Clin Microbiol Rev       Date:  2022-03-09       Impact factor: 50.129
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.